Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Pantel

Showing results (141-150 of 153) with videos related to

Pageof 16
Sort By:
British Journal of Cancer|April 17, 2015
Circulating tumour cell-derived plastin3 is a novel marker for predicting long-term prognosis in patients with breast cancerH Ueo, K Sugimachi, T M Gorges, et al.
British Journal of Cancer|November 27, 2008
Comparison of bone marrow, disseminated tumour cells and blood-circulating tumour cells in breast cancer patients after primary treatmentM J Slade, R Payne, S Riethdorf, et al.
International Journal of Cancer|January 21, 2016
A novel microfluidic platform for size and deformability based separation and the subsequent molecular characterization of viable circulating tumor cellsG E Hvichia, Z Parveen, C Wagner, et al.
Cytotherapy|April 30, 2010
Standardization of the immunocytochemical detection of cancer cells in BM and blood: I. establishment of objective criteria for the evaluation of immunostained cellsE Borgen, B Naume, J M Nesland, et al.
Translational Oncology|May 29, 2021
ViBiBa: Virtual BioBanking for the DETECT multicenter trial program - decentralized storage and processingH Asperger, J-P Cieslik, B Alberter, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 13, 2018
Trastuzumab versus observation for HER2 nonamplified early breast cancer with circulating tumor cells (EORTC 90091-10093, BIG 1-12, Treat CTC): a randomized phase II trialM Ignatiadis, S Litière, F Rothe, et al.
ESMO Open|November 28, 2021
Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study programV Müller, M Banys-Paluchowski, T W P Friedl, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 9, 2022
ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working GroupJ Pascual, G Attard, F-C Bidard, et al.
Plos One|June 7, 2017
The HER2 phenotype of circulating tumor cells in HER2-positive early breast cancer: A translational research project of a prospective randomized phase III trialB A S Jaeger, J Neugebauer, U Andergassen, et al.
Leukemia|March 5, 2020
Correction: Role of growth arrest-specific gene 6-mer axis in multiple myelomaJ S Waizenegger, I Ben-Batalla, N Weinhold, et al.
Pageof 16

Showing results (141-150 of 153) with videos related to

Sort By:
Pageof 16
British Journal of Cancer|April 17, 2015
Circulating tumour cell-derived plastin3 is a novel marker for predicting long-term prognosis in patients with breast cancerH Ueo, K Sugimachi, T M Gorges, et al.
British Journal of Cancer|November 27, 2008
Comparison of bone marrow, disseminated tumour cells and blood-circulating tumour cells in breast cancer patients after primary treatmentM J Slade, R Payne, S Riethdorf, et al.
International Journal of Cancer|January 21, 2016
A novel microfluidic platform for size and deformability based separation and the subsequent molecular characterization of viable circulating tumor cellsG E Hvichia, Z Parveen, C Wagner, et al.
Cytotherapy|April 30, 2010
Standardization of the immunocytochemical detection of cancer cells in BM and blood: I. establishment of objective criteria for the evaluation of immunostained cellsE Borgen, B Naume, J M Nesland, et al.
Translational Oncology|May 29, 2021
ViBiBa: Virtual BioBanking for the DETECT multicenter trial program - decentralized storage and processingH Asperger, J-P Cieslik, B Alberter, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 13, 2018
Trastuzumab versus observation for HER2 nonamplified early breast cancer with circulating tumor cells (EORTC 90091-10093, BIG 1-12, Treat CTC): a randomized phase II trialM Ignatiadis, S Litière, F Rothe, et al.
ESMO Open|November 28, 2021
Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study programV Müller, M Banys-Paluchowski, T W P Friedl, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 9, 2022
ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working GroupJ Pascual, G Attard, F-C Bidard, et al.
Plos One|June 7, 2017
The HER2 phenotype of circulating tumor cells in HER2-positive early breast cancer: A translational research project of a prospective randomized phase III trialB A S Jaeger, J Neugebauer, U Andergassen, et al.
Leukemia|March 5, 2020
Correction: Role of growth arrest-specific gene 6-mer axis in multiple myelomaJ S Waizenegger, I Ben-Batalla, N Weinhold, et al.
Pageof 16